期刊文献+

糖耐量减低患者血清脂联素水平及其相关因素分析

原文传递
导出
摘要 目的测定糖耐量减低患者血清脂联素水平,探讨其与胰岛素抵抗关系。方法用放射免疫分析方法(R IA)测定25例糖耐量减低患者及20例正常对照组的血清脂联素水平,同时测定其空腹血糖(FBG)和餐后2小时血糖(P2hBG)及空腹胰岛素(FINS),并用HOMA稳态模型计算胰岛素抵抗指数(HOMA-IR)。结果(1)在糖耐量减低组和正常对照组血清脂联素值各为(7.69±2.98)mg/L和(11.40±3.72)mg/L,胰岛素抵抗指数各为0.44±0.43和0.20±0.12;两组比较,在糖耐量减低组脂联素值低于正常对照组而HOMA-IR值明显高于正常对照组,比较均有显著性差异(P<0.01);(2)在糖耐量减低组血清脂联素水平与腰围(WC)、腰臀比(WHR)、甘油三酯(TG)成明显负相关,WC、TG、P2hBG是脂联素独立影响因素。结论在糖耐量减低阶段血清脂联素水平已明显降低,并与中心型肥胖、TG、餐后血糖相关,是反映胰岛抵抗的一个重要参数。
出处 《临床内科杂志》 CAS 2006年第4期274-275,共2页 Journal of Clinical Internal Medicine
  • 相关文献

参考文献4

  • 1Lindsay RS,Funahashi T,Hanson RL,et al.Adiponectin and development of type 2 diabetes in the Pima Indian population.Lancet,2002,360:57-58.
  • 2Stefan N,Vozariva B,Funahashi T,et al.Plasma adiponectin concentration is associated with skeletal muscle insulin recepter tyrosine phosphorylation,and low plasma concentration precedes a decrease in whole-body insulin sensitivity.Diabetes,2002,51:1884-1888.
  • 3李晓红,闫胜利.2型糖尿病患者血清脂联素水平变化及其与胰岛素抵抗关系的探讨[J].中国药物与临床,2004,4(7):513-517. 被引量:9
  • 4Philip KG,Gregorio D,Lu T,et al.Adiponectin expression from human adipose tissue:relation to obesity,insulin resistance and tumor necrosis-α expression.Diabetes,2003,52:1779-1785.

二级参考文献15

  • 1[1]Yoda-Murakami M, Taniguchi M, Takahashi K, et al. Change in expression of GBP28/adiponectin in carbon tetrachloride administrated mouse liver. Biochem Biophys Res Commun, 2001, 285:372-377.
  • 2[2]Nakano Y, Tobe T, Choi-Miura NH, et al. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from humpa plasma. J Biochem (Tokyo), 1996, 120: 803-812.
  • 3[3]Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab, 2001,86: 1930-1935.
  • 4[4]Hotta K, Funahashi T, Bodkin NL, et al. Circulating oncentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes, 2001, 50: 1126-1133.
  • 5[5]Takahashi M, Arita Y, Yamagata K, et al. Genomic structure and mutations in adipose-specific gene, adiponectin. Int J Obes Relat Metab Disord, 2000, 24: 861-868.
  • 6[6]Lindsay RS, Funahashi T, Hanson RL, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population.Lancet, 2002, 360:57-58
  • 7[7]Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med, 2001, 7: 941-946.
  • 8[8]Statnick MA, Beavers LS, Conner LJ, et al. Decreased expression of apM1 in omental and subcutaneous adipose tissue of humans with type 2 diabetes. Int J Exp Diabetes Res, 2000, 1: 81-88.
  • 9[9]Yudkin JS. Abnormalities of coagulation and fibrinolysis in insulin resistance. Diabetes Care, 1999, 22(Suppl 3): C25-30
  • 10[10]YokotaT, Oritani K, Takahashi I, et al. Adiponectin, anew member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood, 2000, 96: 1723-1732.

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部